Skip to Content

Lypholyte II (intravenous electrolyte solution) Disease Interactions

There are 2 disease interactions with Lypholyte II (intravenous electrolyte solution):

Major

Intravenous electrolyte solution (applies to Lypholyte II) severe CV/renal/hepatic failure

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hyperkalemia, Fluid Retention, Cardiovascular Disease, Renal Dysfunction, Liver Disease

The use of intravenous electrolyte solution (multiple electrolyte additive) is contraindicated in pathological conditions where additives of potassium, sodium, calcium, magnesium or chloride could be clinically deleterious, e.g., anuria, hyperkalemia, heart block or myocardial damage and severe edema due to cardiovascular, renal or hepatic failure.

Moderate

Intravenous electrolyte solution (applies to Lypholyte II) aluminum toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Intravenous electrolyte solution products contain aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature. High aluminum levels are associated with central nervous system and bone toxicity. Caution is advised when using this products in patients with renal impairment.

Lypholyte II (intravenous electrolyte solution) drug interactions

There is 1 drug interaction with Lypholyte II (intravenous electrolyte solution)

More about Lypholyte II (intravenous electrolyte solution)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.